Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma

Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study

The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.

Inclusion Criteria:

• Patients over 18 years of age
• Metastatic urothelial carcinoma
• Treated with first-line metastatic therapy since October 2024

Exclusion Criteria:

• Patient who expressed opposition to participating in the study